Although the effect of alisertib on the immune microenvironment is not fully understood (12), these responses of the immune microenvironment to AURKA inhibition may contribute to the suppression of tumor progression and increased responsiveness to anti–B7-H3 therapy. The gene discussed is CD276; the disease is neoplasm.